Indian drugmakers – including Sun Pharmaceutical Industries, Zydus Lifesciences, and Dr. Reddy’s Laboratories have launched generic versions of semaglutide injections following the expiration of the drug’s patent. The development significantly improves affordability and access for patients managing Type 2 Diabetes and obesity in India.
Competitive Launches Drive Down Treatment Costs
The launches came shortly after Natco Pharma introduced its generic semaglutide injection, priced at approximately ₹1,290 per month. Subsequently, other major players entered the market, intensifying competition and driving down prices. As a result, patients now have access to a wider range of cost-effective treatment options.
Diverse Product Offerings Across Companies
Each company has introduced multiple formulations tailored to different patient needs. Semaglutide belongs to the GLP-1 receptor agonist class of drugs, which have a well-established global track record. India’s pharmaceutical industry continues to expand rapidly. According to the Ministry of Commerce and Industry, pharma exports grew by 9.4% in 2024–25, reaching $30.47 billion.
Expanding Access and Strengthening Global Position
As reported by ndtv.com, the launch of low-cost generic semaglutide marks a major step toward affordable healthcare in India. By increasing competition and reducing prices, Indian pharmaceutical companies are not only improving patient access but also strengthening the country’s leadership in global generic drug manufacturing.
